Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an immune-mediated demyelinating disorder that affects the central nervous system by causing inflammation and damage to the optic nerve, spinal cord, brain, and/or brainstem. The MOG protein is found in the nerve coverings of the central nervous system and is involved in myelin maturation and cell surface interactions. The exact cause of MOGAD is unknown, and it affects males and females equally but is more prevalent in children than adults. The symptoms of MOGAD are categorized into optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), and cerebral encephalitis. Diagnosing MOGAD requires a blood test to screen for antibodies and MRI and lumbar puncture.

·       In the USA, the estimated incidence of MOGAD is 1 to 2 per 100,000 individuals annually.

Thelansis’s “Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033